<- Go Home
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. develops novel therapeutic products for the acute treatment of migraines. Its product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery devices. The company was incorporated in 2016 and is based in Durham, North Carolina. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
Market Cap
$36.5M
Volume
282.9K
Cash and Equivalents
$19.5M
EBITDA
-$53.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$8.08
52 Week Low
$0.59
Dividend
N/A
Price / Book Value
0.97
Price / Earnings
-0.55
Price / Tangible Book Value
0.97
Enterprise Value
-$4.8M
Enterprise Value / EBITDA
0.09
Operating Income
-$54.4M
Return on Equity
104.04%
Return on Assets
-49.62
Cash and Short Term Investments
$41.4M
Debt
$116.0K
Equity
$37.6M
Revenue
N/A
Unlevered FCF
-$24.9M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium